Evaluation of tumor angiogenesis using dynamic enhanced magnetic resonance imaging: Comparison of plasma vascular endothelial growth factor, hemodynamic, and pharmacokinetic parameters

Acta Radiologica

Volumn 45, Issue 4, 2004, Pages 446-452

  Ikeda, O ^a   Nishimura, R ^b   Miyayama, H ^b   Yasunaga, T ^b   Ozaki, Y ^b   Tuji, A ^b   Yamashita, Y ^b  

^a KUMAMOTO UNIVERSITY   (Japan)

^b NONE

Author keywords

Magnetic resonance imaging; Plasma VEGF; Tumor angiogenesis

Indexed keywords

BLOOD VESSELS; GROWTH KINETICS; HEMODYNAMICS; MATHEMATICAL MODELS; PHARMACOKINETICS; RADIOLOGY; TUMORS;

IMAGE DATA; PLASMA VEGF; TUMOR ANGIOGENESIS;

MAGNETIC RESONANCE IMAGING;

CONTRAST MEDIUM; DIAGNOSTIC AGENT; GADOLINIUM PENTETATE; VASCULOTROPIN A;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; BIOLOGICAL MODEL; BLOOD; BLOOD FLOW; BREAST TUMOR; COMPARATIVE STUDY; FEMALE; HUMAN; IMAGE ENHANCEMENT; IMAGE PROCESSING; METHODOLOGY; MIDDLE AGED; NEOVASCULARIZATION (PATHOLOGY); NUCLEAR MAGNETIC RESONANCE IMAGING; PERMEABILITY; PHYSIOLOGY; TIME; VASCULARIZATION;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CONTRAST MEDIA; FEMALE; GADOLINIUM DTPA; HUMANS; IMAGE ENHANCEMENT; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; MODELS, BIOLOGICAL; NEOVASCULARIZATION, PATHOLOGIC; PERMEABILITY; REGIONAL BLOOD FLOW; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 4444239697     PISSN: 02841851     EISSN: None     Source Type: Journal    
DOI: 10.1080/02841850410005372     Document Type: Article

References (32)

1. Adams J, Carder PJ, Downey S, Forbes AM, Maclennan K, Allgar V, et al. Vascular endothelial growth factor (VEGF) in breast cancer: comparison of plasma, serum, and tissue VEGF and microvessel density and effects of tamoxifen. Cancer Res 2000; 60:2898-905.
2. Banks RE, Forbes MA, Kinsey SE, Stanley A, Ingham E, Walters E, et al. Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. Br J Cancer 1998;77:956-64.
3. Breoer G, Albrecht U, Sterrer S, Risau W. Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation: development 1992;114:521-32.
4. Buadu LD, Murakami J, Murayama S, Hashiguchi S, Sakai S, Masuda K, et al. Breast lesions: correlation of contrast medium enhancement patterns on MR images with histopathologic findings and tumor angiogenesis. Radiology 1996;200:639-49.
5. Eppenberger U, Kueng W, Schlaeppi JM, Roesel LJ, Benz C, Mueller H, et al. Markers of tumor angiogenesis and proteolysis independently define high- and low-risk subsets of node-negative breast cancer patients. J Clin Oncol 1998;16:3129-36.
6. Flickinger FW, Allison JD, Sherry RM, Wright JC. Differentiation of benign from malignant breast masses by time-intensity evaluation of contrast enhanced MRI. Magn Reson Imag 1993;11:617-20.
7. Foekens JA, Peters HA, Grebenchtchikov N, Look PM, Gelder M, Geurts-Moespot A, et al. High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. Cancer Res 2001;61:5407-414.
8. Folkman J, Watson K, Ingber D, Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989;339:58-61.
9. Gasparini G, Barbareschi M, Boracchi P, Boracchi P, Verderio P, Caffo O, et al. Tumor angiogenesis predicts clinical outcome of node-positive breast cancer patients treated with adjuvant hormone therapy or chemotherapy Cancer. J Sci Am 1995;1:131-42.
10. Gilles R, Guinebretiere JM, Lucidarme O, Cluzel P, Janaud G, Finet JF, et al. Nonpalpable breast tumors: diagnosis with contrast-enhanced subtraction dynamic MR imaging. Radiology 1994;191:625-31.
11. Gimbrone Jr. M, Leapman S, Cotran R, Folkman J. Tumor dormancy in vivo by prevention of neovascularisation. J Exp Med 1972;136:261-76.
12. Gribbesttad SI, Nilsen G, Fjosne H, Fougner R, Hangen AO, Petersen BS, et al. Contrast-enhanced magnetic resonance imaging of the breast. Acta Oncol 1992;193:833-42.
13. Hanan S, Ahmed-Emad M, Hans O, Jose H, Jens-Uwe B, Matthias T, et al. Peripheral washout sign on contrast-enhanced MR imagines of the breast. Radiology 1997;205:209-13.
14. Harms SE, Flaming DP, Hesley KL, Meiches MD, Jensen RA, Evans WP, et al. MR imaging of the breast with rotating delivery of excitation off resonance: clinical experience with pathologic correlation. Radiology 1993;187:493-501.
15. Heywang-Koebrunner SH, Haustein J, Pohl C, Beck R, Lommatzsch B, Untch M, et al. Contrast-enhanced MR imaging of the breast: comparison of two different doses of gadopentetate dimeglumine. Radiology 1994; 191:639-46.
16. Hulka PS, Smith BL, Sgrori DC, Tan L, Edmister WB, Semple JP, et al. Benign and malignant breast lesions: differentiation with echo-planar MR imaging. Radiology 1995;197:33-8.
17. Ikeda O, Yamashita Y, Morishita S, Kido T, Kitajima M, Okamura K, et al. Characterization of breast masses by dynamic enhanced MR imaging: a logistic analysis. Acta Radiol 1999;40:585-92.
18. Ikeda O, Yamashita Y, Morishita S. Gd-enhanced dynamic magnetic resonance imaging of breast masses. Topics in MRI 1999;10:143-51.
19. Jacques AB, Ruud KKMH, Jouke S, Gerard D, Paul WAA, Jan HM, et al. Pharmacokinetic analysis of Gd-DTPA enhancement in dynamic three-dimensional MRI of breast lesions. JMRM 1997;7:702-15.
20. Kaiser WA, Zeitler E. MR imaging of the breast: fast imaging sequences with and without Gd-DTPA. Radiology 1989;193:681-6.
21. Kelsey JL. A review of the epidemiology of human breast cancer. Epidemiol Rev 1979;1:74-109.
22. Kirsten LW, Cynthia FM, Brian KR, Medeleine M. Invasive carcinomas and fibroadenomas of the breast: comparison of mirovessel distributions - implications for imaging modalities. Radiology 1998;208:477-83.
23. Koide N, Nishio A, Hiraguri M, Hanazaki K, Adachi W, Amano J. Coexpression of vascular endothelial growth factor and p53 protein in squamous cell carcinoma of the esophagus. Am J Gastroenterol 2001; 96:1733-40.
24. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989;246:1306-9.
25. Liberman L, LaTrenta L, Dershaw D, Abramson AF, Morris EA, Cohen MA, et al. Impact of core biopsy on the surgical management of impalpable breast cancer. Am J Roentgenol 1997;168:495-9.
26. Liberman L, LaTrenta L, VanZee KJ, Morris EA, Abramson AF, Dershaw DD. Stereotactic core biopsy of calcifications highly suggestive of malignancy. Radiology 1997;203:673-7.
27. Oral SG, Schnall MD, LiVolsi VA, Troupin RH. Suspicious breast lesions: MR imaging with radiologic - pathologic correlation. Radiology 1994;190:485-93.
28. Salven P, Perhoniemi V, Tykka H, Maenpaa H, Joensuu H. Serum VEGF levels in women with a benign breast tumor or breast cancer. Breast Cancer Res Treat 1999;53:161-6.
29. Tofts PS, Kermode AG. Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts. Magn Reson Med 1991;17:357-67.
30. Toi M, Inada K, Suzuki H, Tominaga T. Tumor angiogenesis in breast cancer: its importance as a prognostic indicator and the association with vascular endothelial growth factor expression. Br J Cancer Res Treat 1995;36:193-204.
31. Turkat TJ, Klein BD, Polan RL, Richman HR. MR mammography: a technique for potentially reducing the biopsy rate for benign breast disease. J Magn Reson Imag 1994;4:563-8.
32. Verheul HM, Hoekman K, Luykx-de Bakker S, Eekman AC, Folman CC, Broxterman JH, et al. Platelet: transporter of vascular endothelial growth factor. Clin Cancer Res 1997;3:2187-90.